Skip to main navigation Skip to search Skip to main content

Risk factors for bleeding during treatment of acute venous thromboembolism

  • Jos P.J. Wester
  • , Harold W. De Valk
  • , H. Karel Nieuwenhuis
  • , Catherine B. Brouwer
  • , Yolanda Van Der Graaf
  • , Otger J.A.Th Meuwissen
  • , Herman C. Hart
  • , Jan J. Sixma
  • , Jan Dirk Banga

Research output: Contribution to journal › Article › Academic › peer-review

50 Citations (Scopus)

Abstract

Objective: Identification of risk factors for bleeding and prospective evaluation of two bleeding risk scores in the treatment of acute venous thromboembolism. Design: Secondary analysis of a prospective, randomized, assessor-blind, multicenter clinical trial. Setting: One university and 2 regional teaching hospitals. Patients: 188 patients treated with heparin or danaparoid for acute venous thromboembolism. Measurements: The presenting clinical features, the doses of the drugs, and the anticoagulant responses were analyzed using univariate and multivariate logistic regression analysis in order to evaluate prognostic factors for bleeding. In addition, the recently developed Utrecht bleeding risk score and Landefeld bleeding risk index were evaluated prospectively. Results: Major bleeding occurred in 4 patients (2.1%) and minor bleeding in 101 patients (53.7%). For all (major and minor combined) bleeding, body surface area ≤2 m2 (odds ratio 2.3, 95% CI 1.2-4.4; p = 0.01), and malignancy (odds ratio 2.4, 95% CI 1.1-4.9; p = 0.02) were confirmed to be independent risk factors. An increased treatment related risk of bleeding was observed in patients treated with high doses of heparin, independent of the concomitant activated partial thromboplastin time ratios. Both bleeding risk scores had low diagnostic value for bleeding in this sample of mainly minor bleeders. Conclusions: A small body surface area and malignancy were associated with a higher frequency of bleeding. The bleeding risk scores merely offer the clinician a general estimation of the risk of bleeding. In patients with a small body surface area or in patients with malignancy, it may be of interest to study whether limited dose reduction of the anticoagulant drug may cause less bleeding without affecting efficacy.

Original languageEnglish
Pages (from-to)682-688
Number of pages7
JournalThrombosis and Haemostasis
Volume76
Issue number5
DOIs
Publication statusPublished - Nov 1996

Fingerprint

Dive into the research topics of 'Risk factors for bleeding during treatment of acute venous thromboembolism'. Together they form a unique fingerprint.

Cite this